Clinical expert consensus on the assessment and protection of pancreatic islet ll-cell function in type 2 diabetes mellitus

Islet ll-cell dysfunction is a basic pathophysiological characteristic of type 2 diabetes mellitus (T2DM). Appro-priate assessment of islet ll-cell function is beneficial to better management of T2DM. Protecting islet ll-cell function is vital to delay the progress of type 2 diabetes mellitus. Therefore, the Pancreatic Islet ll-cell Expert Panel of the Chinese Diabetes Society and Endocrinology Society of Jiangsu Medical Association organized experts to draft the Clinical expert consensus on the assessment and protection of pancreatic islet fl-cell function in type 2 diabetes mellitus. This consensus suggests that 8 -cell function can be clinically assessed using blood glucose -based methods or methods that combine blood glucose and endogenous insulin or C-peptide levels. Some measures, including weight loss and early and sustained euglycemia control, could effectively protect islet 8 -cell function, and some newly developed drugs, such as Sodium-glucose cotransporter-2 inhibitor and Glucagon-like peptide-1 receptor agonists, could improve islet 8 -cell function, independent of glycemic control.

Automated summary

This article discusses the pathophysiological characteristic of β-cell dysfunction in type 2 diabetes mellitus (T2DM) and highlights the importance of assessing and protecting β-cell function. β-cell function can be clinically assessed using methods based on blood glucose or methods that combine blood glucose and endogenous insulin or C-peptide levels. Measures such as weight loss and early and sustained euglycemia control can effectively protect β-cell function, while newly developed drugs such as Sodium-glucose cotransporter-2 inhibitors and Glucagon-like peptide-1 receptor agonists can improve β-cell function independently of glycemic control.